JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

Cogent Biosciences Inc

Chiusa

11.82 -2.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.66

Massimo

12.16

Metriche Chiave

By Trading Economics

Entrata

-4.1M

-72M

Dipendenti

205

EBITDA

-1.2M

-74M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+62.45% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.1B

1.7B

Apertura precedente

14.05

Chiusura precedente

11.82

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 lug 2025, 23:57 UTC

Acquisizioni, Fusioni, Takeovers

EQT: To Spend Y407.82B for Tender Offer

29 lug 2025, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

EQT: Tender Offer Price Is Y5,700 a Share

29 lug 2025, 23:54 UTC

Acquisizioni, Fusioni, Takeovers

EQT To Start Tender Offer for Fujitec

29 lug 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 lug 2025, 23:36 UTC

Discorsi di Mercato

Gold Steady Ahead of FOMC Decision -- Market Talk

29 lug 2025, 22:57 UTC

Discorsi di Mercato

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 lug 2025, 22:50 UTC

Discorsi di Mercato

Mondelez Warns of Price Increases in North America -- Market Talk

29 lug 2025, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 lug 2025, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 lug 2025, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 lug 2025, 22:35 UTC

Utili

IGO Maintains Nova Life of Mine Production Guidance

29 lug 2025, 22:35 UTC

Utili

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 lug 2025, 22:35 UTC

Utili

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 lug 2025, 22:34 UTC

Utili

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 lug 2025, 22:34 UTC

Utili

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 lug 2025, 22:34 UTC

Discorsi di Mercato
Utili

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 lug 2025, 22:33 UTC

Utili

IGO Had A$279.7 Million of Cash at End-June

29 lug 2025, 22:33 UTC

Utili

IGO 4Q Underlying Free Cash A$2.4 Million

29 lug 2025, 22:33 UTC

Utili

IGO FY Sales Revenue A$512.5 Million

29 lug 2025, 22:33 UTC

Utili

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 lug 2025, 22:32 UTC

Utili

IGO FY Nickel Production 17,173 Tons

29 lug 2025, 22:32 UTC

Utili

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 lug 2025, 22:32 UTC

Utili

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 lug 2025, 22:31 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

29 lug 2025, 22:31 UTC

Discorsi di Mercato
Utili

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 lug 2025, 22:31 UTC

Utili

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 lug 2025, 22:31 UTC

Utili

IGO FY Spodumene Production 1.48 Million Tons

29 lug 2025, 22:30 UTC

Utili

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 lug 2025, 22:30 UTC

Utili

IGO 4Q Underlying Ebitda A$62 Million

29 lug 2025, 22:22 UTC

Utili

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

62.45% in crescita

Previsioni per 12 mesi

Media 19.64 USD  62.45%

Alto 29 USD

Basso 9 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

9

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Strong Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.